Ranibizumab for Neovascular Age-Related Macular Degeneration

To the Editor: The results of the MARINA (Minimally Classic/Occult Trial of the Anti-VEGF Antibody Ranibizumab in the Treatment of Neovascular Age-Related Macular Degeneration) study and the ANCHOR (Anti-VEGF Antibody for the Treatment of Predominantly Classic Choroidal Neovascularization in Age-Related Macular Degeneration) study (Oct. 5 issue)^1,2 show the remarkable and reassuring safety of ranibizumab in the treatment of neovascular age-related macular degeneration. We are concerned, however, by the low reported rate of arterial thromboembolic events in both ranibizumab groups (4.6% over a period of 2 years among patients receiving 0.3 mg or 0.5 mg) and sham injection (3.8%) in . . .